Evidence map›Paper›PMID 23261593›Full record

ArticleChemistry & biology2012

A new drug for an old bug.

Peter J Myler, Robin Stacy

Abstract readComment
In one paragraph

Article in Chemistry & biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. A Systematic Strategy to Find Potential Therapeutic Targets forFrontiers in molecular biosciences · 2021
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Peter J Myler
Robin Stacy
Center for Infectious Disease Research · US

Funding

NIAID NIH HHS HHSN272201200025CPHS HHS HHSN27220120025C
6 · The paper itself

Abstract

There is an urgent need to develop new drugs for the treatment of tuberculosis, particularly against latent/persistent forms of the causative agent, Mycobacterium tuberculosis. In this issue of Chemistry & Biology, Krieger and colleagues use a structure-guided approach to develop novel inhibitors of malate synthase, a target in the glyoxylate shunt that is critical for pathogen survival in chronic infection.

Identifiers

PMID23261593
PMCPMC3536450
OpenAlexW2158550277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.